Avatrombopag

Bussel, James B.

doi:10.1111/bjh.15568

Cited by 6 publications

(3 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was a thrombopoietin receptor agonist that bound to the thrombopoietin (TPO) receptor in the transmembrane domain and could be taken orally. Not only was it very effective, but it could be taken orally daily and there were no dietary restrictions [16] .…”

Section: Discussionmentioning

confidence: 99%

Severe Pneumonia With Thrombocytopenia Caused By Chlamydia Psittaci: A Case And Literature Review

Shi

Wang

Chen

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: Severe pneumonia caused by Chlamydia psittaci is a rare infectious disease associated with living environment. The causes of thrombocytopenia were infection, leukemia, idiopathic thrombocytopenia and many other factors. The determination of platelet parameters could reflect the compensatory situation of bone marrow and provide a basis reason of thrombocytopenia identification. Case presentation: Based on the patient’s symptoms, exposure history, computerized tomography（CT）and next-generation sequencing, a preliminary diagnosis of the patient were made, at the same time other infections are excluded. We reported a case of severe pneumonia with severe thrombocytopenia caused by Chlamydia psittaci. During the treatment, he was diagnosed as parrot fever and secondary immune thrombocytopenia. Anti-infection and rising platelet with Doptelet treatment were in effect. The presence of high fever, feeling faint, gastrointestinal symptoms, images of chest CT and platelet reduction, Chlamydia psittaci might be considered as a priority reason of this case, other infections and hematology disorders excluded.Conclusion: This is the first reported case of Chlamydia psittaci-induced thrombocytopenia associated with bone marrow changes and treatment. The efficacy of mokexin in the treatment of thrombocytopenia may be further generalized.

show abstract

Section: Discussionmentioning

confidence: 99%

Severe Pneumonia With Thrombocytopenia Caused By Chlamydia Psittaci: A Case And Literature Review

Shi

Wang

Chen

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…In fact, eltrombopag should be taken on an empty stomach with no food 2 h before and after the drug consumption, and no calcium- or iron-containing products or supplements for 4 h before and after the drug consumption. In contrast, all the newly FDA-approved drugs are orally effective, and their absorption profiles are less impacted by food consumption with no anticipated effect presented by supplements containing polyvalent cations [73].…”

Section: Discussionmentioning

confidence: 99%

New Small Molecule Drugs for Thrombocytopenia: Chemical, Pharmacological, and Therapeutic Use Considerations

Bankston

Al‐Horani

2019

IJMS

View full text Add to dashboard Cite

This review provides details about three small molecules that were recently approved by the FDA for the treatment of thrombocytopenia. The new treatments include lusutrombopag, avatrombopag, and fostamatinib. The first two drugs are orally active thrombopoietin receptor (TPO-R) agonists which are FDA-approved for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure. Fostamatinib is orally active prodrug that, after activation, becomes spleen tyrosine kinase (SYK) inhibitor. Fostamatinib is currently used to treat chronic and refractory immune thrombocytopenia in patients who have had insufficient response to previous treatment. Chemical structures, available dosage forms, recommended dosing, pharmacokinetics, results of toxicity studies in animals, most frequent adverse effects, significant outcomes of the corresponding clinical trials, and their use in specific patient populations are thoroughly described. Described also is a comparative summary of the different aspects of five currently available therapies targeting TPO-R or SYK for the treatment of thrombocytopenia.

show abstract

“…It is similar to eltrombopag in binding to the TPO-receptor in the transmembrane domain, being available orally and in its efficacy. However, no interactions with food were recorded (24). The TPO-RAs are still developing.…”

Section: Tpo-ramentioning

confidence: 91%

Treating ITP: What are the options in the era of new guidelines and new drugs?

Pantić¹,

Suvajdzic-Vukovic²

2020

Medicinski podmladak

View full text Add to dashboard Cite

Primary immune thrombocytopenia (ITP) is an autoimmune disease characterized by isolated thrombocytopenia. Treating ITP may be challenging since different treatment modalities are available. While choosing the suitable option for every patient, a physician should take into account both patient's medical characteristics and wishes. The first line treatment options include: corticosteroids, intravenous immunoglobulins and intravenous anti-D immunoglobulin. Second line treatment options comprise medical (thrombopoietin receptor agonists, rituximab, fostamatinib, azathioprine, cyclophosphamide, cyclosporin A, hydroxychloroquine, mycophenolate mofetil, danazol, dapsone, vinca-alcaloids) and surgical (splenectomy) approach. However, there are some treatment gaps which remain uncovered with existing treatment modalities. Therefore, development of novel therapeutic strategies is required. The aim of this review is to provide an illustrative overview of novel treatments for adult ITP.

show abstract

Avatrombopag

Cited by 6 publications

References 13 publications

Severe Pneumonia With Thrombocytopenia Caused By Chlamydia Psittaci: A Case And Literature Review

Severe Pneumonia With Thrombocytopenia Caused By Chlamydia Psittaci: A Case And Literature Review

New Small Molecule Drugs for Thrombocytopenia: Chemical, Pharmacological, and Therapeutic Use Considerations

Treating ITP: What are the options in the era of new guidelines and new drugs?

Contact Info

Product

Resources

About